1383 related articles for article (PubMed ID: 24373150)
1. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
5. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
6. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
7. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
9. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
Iepsen EW; Torekov SS; Holst JJ
Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
Mundil D; Cameron-Vendrig A; Husain M
Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
12. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
Ryder RE
Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
Cariou B
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
17. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
Madsbad S
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
[TBL] [Abstract][Full Text] [Related]
18. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
19. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]